-
March 11, 2022 Lupin Receives Approval from U.S. FDA for Vigabatrin for Oral Solution USP
-
March 10, 2022 Lupin Launches its First Reference Laboratory in East India Establishing its Diagnostics Business in Kolkata
-
March 9, 2022 Lupin Teams up with Mary Kom to Raise Awareness Amongst Women on Cardiovascular Disease
-
March 7, 2022 Lupin signs on Mary Kom for its Women’s Cardiovascular Health Awareness Initiative, Shakti
-
March 3, 2022 Lupin Receives Approval from U.S. FDA for Efinaconazole Topical Solution
-
March 1, 2022 Lupin Launches Sevelamer Hydrochloride Tablets in the United States
-
February 23, 2022 Lupin Announces Executive Leadership Change, Dr. Fabrice Egros to assume Corporate Development responsibilities as President, Corporate Development & Growth Markets
-
February 17, 2022 Lupin Announces FDA Approval of Supplemental New Drug Application for SOLOSEC® (secnidazole) in Adolescents for both the Treatment of Bacterial Vaginosis in Females and Trichomoniasis
-
February 9, 2022 Lupin Signs Distribution Agreement with Medis for Orphan Drug NaMuscla®
In this section
Media Contacts
-
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications